Overview
Financials
Filing timeliness
No financial statement for 2019 – the filing deadline has passed.
- 2019not filed
- 201822/05/2019
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2018.
Results vs industry
Industry
- Manufacture of basic pharmaceutical products (21.1)
Trademarks
KF Niccolum currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2016.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| Nidiesque Protects from NICKEL | Z.462232 | 3, 5, 35 | Expired | – | |
| NIDIESQUE(word) | Z.462233 | 3, 5, 35 | Expired | – |
| Mark | Protected until | |
|---|---|---|
| Nidiesque Protects from NICKEL | – | |
| NIDIESQUE(word) | – |
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Dariusz Skłodowskiage 57 | 21,824 | $294,759.59 | 16.3976% |
Eryk Skłodowskiage 56 | 15,045 | $203,200.97 | 11.3041% |
Tadeusz Skłodowskiage 79 | 39,092 | $527,984.87 | 29.3719% |
Izabela Zawiszaage 39 | 15,410 | $208,130.74 | 11.5784% |
Others | 41,722 | $563,506.21 | 31.348% |
Tadeusz Skłodowski, Dariusz Skłodowski and Eryk Skłodowski hold a combined 57.1% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2015-05-13.
52 1090 1841 0000 0001 3544 5665- 55 1090 1841 0000 0001 3048 6486
Debt
No entries in the National Debtors Register (KRZ).
Public aid
6 public aid cases recorded, with a total value of $202,391.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,101$1,101 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,083$1,083 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Mar 15, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $678$678 | MARSZAŁEK MAZOWIECKI |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-10-01 | Development of a technology for producing substances that chelate chromium and cobalt ions, based on the synthesis of active biopolymers. | $190.6K$190,629 | Regional Operational Programme for the Mazowieckie Voivodeship for 2014-2020 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Proper Medical Writingsp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| DigitmedS.A. | $382,907.91 | digitmed.pl | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| Bactremsp. z o.o. | $181,958.36 | bactrem.pl | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl |
Change history
| Date | Event | |
|---|---|---|
| 2020-01-02 | Share capital increase (4,654,650.00 PLN → 6,654,650.00 PLN) | |
| 2018-09-13 | Share capital increase (1,551,550.00 PLN → 4,654,650.00 PLN) | |
| 2017-11-14 | Share capital increase (750,750.00 PLN → 1,551,550.00 PLN) | |
| 2017-01-17 | Share capital increase (50,050.00 PLN → 750,750.00 PLN) | |
| 2015-08-27 | Share capital increase (40,000.00 PLN → 50,050.00 PLN) |
FAQ
Last updated: 2026-04-11